Published in final edited form as:

Child Adolesc Psychiatr Clin N Am. 2020 January ; 29(1): 157–170. doi:10.1016/j.chc.2019.08.007.

Genetics of Childhood-Onset Schizophrenia: 2019 Update

Jennifer K. Forsyth, Ph.D.¹, Robert F. Asarnow, Ph.D.^{1,2,3}

¹Department of Psychiatry & Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, CA 90095

²Department of Psychology, University of California, Los Angeles, Los Angeles, CA 90095

³Brain Research Institute, University of California, Los Angeles, CA 90095

Keywords

childhood-onset schizophrenia; genetics; common variants; GWAS; copy number variants; rare variants; de novo mutations; autism spectrum disorder

Introduction

Childhood onset schizophrenia (COS) is defined as schizophrenia with onset prior to age 13 and is a rare and early onset variant of the much more common schizophrenia with adult onset (AOS). The prevalence of true COS cases is fewer than 1 in 10,000¹. In contrast, the lifetime prevalence of AOS is 4.0 in 1,000². It should be noted that prior to DSM-III, there was no uniform diagnostic criteria for COS. Early studies of COS therefore included children who today would receive DSM-V³ diagnoses of Autism Spectrum Disorder, Unspecified Neurodevelopmental Disorder, or Schizophrenia, and there were significant variations between clinicians in how COS was diagnosed.

Epidemiological and family studies in the 20th century clearly established that genetic factors play a major role in the etiology of AOS. In the past decade, modern genome-wide association studies have begun to identify many specific genetic factors that are associated with AOS. Due to the low prevalence of COS, less is known about the individual genetic factors that increase risk for COS. Nevertheless, genetic studies of COS have generally paralleled studies of the much more common AOS, and initial findings suggest that many genetic factors that confer risk for AOS also confer risk for COS.

To highlight the historical evolution of genetic studies of COS, in the following, the authors will first discuss familial aggregation studies of AOS and COS. They then provide a brief overview of modern understandings of the human genome and classes of genetic variation as

Corresponding Authors: Jennifer K. Forsyth, Ph.D. and Robert F. Asarnow, Ph.D., 760 Westwood Plaza, Los Angeles, CA 90095, jforysyth@mednet.ucla.edu; rasarnow@mednet.ucla.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

The authors have no conflicts of interest to disclose.

they relate to the genetic architecture of schizophrenia. The authors subsequently provide an overview of major genetic findings for AOS, including reviewing studies of common, rare, and copy number variants in AOS. Finally, the authors will review genetic studies of COS, more specifically. Of note, many modern, large-scale genome-wide association studies of schizophrenia involve minimal patient characterization aside from establishing schizophrenia case status. As such, age of onset is often not reported. Since the vast majority of schizophrenia patients have their first psychotic episode in adulthood, the authors will refer to studies of broadly ascertained schizophrenia patients as AOS studies. In addition, in the discussion of familial aggregation studies, the authors focus on studies that examined risk in parents of schizophrenia probands rather than risk in siblings, because the siblings of COS probands typically have not entered the classical age of risk for schizophrenia.

Familial aggregation of schizophrenia

Initial genetic studies of AOS and COS examined family members of patients with AOS or COS to test the hypotheses that schizophrenia and/or schizophrenia spectrum disorders show familial aggregation. Every modern study that used relatively narrow, operationalized criteria for schizophrenia found that schizophrenia strongly aggregated in families of AOS patients relative to families of community controls. Modern family studies found a three-fold increase in the relative risk (RR) for schizophrenia among parents of AOS probands compared to the parents of controls⁴. Similarly, the morbid schizophrenia risk for parents and siblings of AOS probands was 6% and 9%, respectively, compared to 1% in the general population⁵. Adoption and twin studies further suggested that the increased risk of schizophrenia among family members of AOS probands was largely due to shared genetic factors, rather than shared environmental factors⁴.

In studies of COS, an early twin study found a concordance for COS diagnosis for monozygotic twins of 88.2% compared with a concordance of 22.3% in dizygotic twins⁶. This yielded a heritability estimate of 84.5%, suggesting that COS is highly heritable. Two modern studies that used DSM III-R criteria and collected data through both personal interview and interviews of family members similarly suggested that schizophrenia aggregates in the families of COS probands. Thus, the UCLA study found a RR of 17 for schizophrenia in the parents of COS probands compared to those of controls⁷. The NIMH Child Psychiatry Branch study of 95 COS patients found one case of schizophrenia in parents of COS probands and none in parents of community control probands⁸. Together, these family aggregation studies suggested that genes may play a role in the etiology of schizophrenia.

Familial aggregation of schizophrenia spectrum disorders

Family studies also found that in addition to schizophrenia, a number of other psychiatric disorders tend to aggregate in families of AOS probands. These are termed “schizophrenia spectrum disorders,” and include Schizoaffective Disorder (depressed type), Schizotypal Personality Disorder, Schizophreniform and Atypical Psychosis, and Paranoid Personality Disorder. The only two studies which determined the RR of schizophrenia spectrum disorders separately for parents (i.e., not combined with siblings) of AOS probands found

RRs of schizotypal personality and/or paranoid personality disorders of 6.6⁹ and 3.0¹⁰ in parents of AOS probands.

In the two modern family studies of COS, the RR for schizotypal personality and/or paranoid personality disorders in parents of COS probands was 10.5⁷ and 15.2⁸. When schizophrenia was included as a schizophrenia spectrum disorder, the RR for schizophrenia spectrum disorders was 16.9⁷ and 15.9⁸ in parents of COS probands. The RR for just schizophrenia, schizotypal or paranoid personality disorders was 15.1 in parents of COS probands⁷. Compared to the RR of 5.8 for schizophrenia, schizotypal, or paranoid personality disorder found in a large family study of AOS probands that used similar diagnostic approaches as the UCLA study⁹, the RR risk of schizophrenia and schizophrenia spectrum disorders appears to be greater in parents of COS probands than in parents of AOS probands. This increased rate of schizophrenia spectrum disorders in relatives of COS probands suggests that schizophrenia spectrum disorders may aggregate more strongly in the families of COS probands compared to AOS probands.

Familial aggregation of neurobiological abnormalities

A number of neurobiological abnormalities present in AOS and COS patients are also present in a substantial number of their non-psychotic first degree relatives. These abnormalities are sometimes referred to as endophenotypes. Endophenotypes are thought to reflect the effects of genetic risk for schizophrenia and are considered “intermediate phenotypes” that may be closer to the biological effects of risk genes than DSM-V symptoms of schizophrenia¹¹. Some have argued that identifying endophenotypes may help elucidate causal pathways between putative risk genes and “their expression as a clinically identifiable phenotype”¹².

Abnormalities found in the non-psychotic relatives of AOS patients include impairments in neurocognitive functioning and smooth pursuit eye-movements, and abnormalities in brain structure and electrical activity^{13,14}. Many similar abnormalities are found in the non-psychotic relatives of COS probands. For example, a combination of scores on three tests that detect neurocognitive deficits in non-psychotic relatives of AOS probands identified 20% of mothers and fathers of COS probands compared to 0% of the mothers or fathers of community control probands. Scores on these neurocognitive tests also showed some diagnostic specificity, with a cutoff that identified 12% of mothers of COS probands identifying 0% of ADHD mothers¹⁵. Non-psychotic first degree relatives of patients with COS also showed impairments in attention/executive function¹⁶ and smooth pursuit eye tracking¹⁷. Non-psychotic siblings of COS probands showed deficits on a procedural skill learning task supported by a cortical-striatal network¹⁸, widespread reductions in white matter microstructural integrity¹⁹, and reduced gray matter volume in a number of cortical and subcortical regions, but increased grey matter volume in the lingual gyrus and cerebellum²⁰. A longitudinal study also found that prior to adolescence, the non-psychotic siblings of COS probands showed reduced cortical gray matter in superior temporal and prefrontal areas²¹; however, these reductions normalized during adolescence. In general, the first degree relatives of patients with COS show subtle impairments on some tasks identified as potential endophenotypes in studies of relatives of AOS patients, suggesting that these

deficits do not merely reflect the effects of psychosis, and instead are likely to reflect genetic factors.

Interestingly, a family study of first and second degree relatives of community controls with and without family histories of schizophrenia found that impairment in neurocognitive functioning and incidence of schizophrenia spectrum disorders were relatively independent expressions of familial liability to schizophrenia²². Given that schizophrenia is a complex, polygenic disorder, the genes associated with neurobiological endophenotypes may not be the same set of genes that are associated with psychotic symptoms. In addition, a recent family study of COS, AOS and community control probands examined familial transmission of neurocognitive function. In AOS families, this study found shared familial effects on *attention* and *working memory*, but not on *verbal learning* and *memory for faces*. By contrast, in COS families there were significant shared familial effects on *verbal learning* and *memory for faces*, but not on *attention* and *working memory*²³. Thus, the familial architecture of neurocognitive functions may differ somewhat between COS and AOS nuclear families.

It is important to recognize that paralleling the heterogeneity of findings in studies of COS and AOS patients, many first-degree relatives of patients with schizophrenia do not have neurobiological abnormalities. However, while there is considerable heterogeneity among relatives in what abnormalities they do have, type of neurocognitive impairment does tend to run in families. The neurobiological abnormalities identified in non-psychotic relatives of COS patients appear to tap diverse neural networks. Heterogeneity of neurobiological abnormalities may indicate that impairments in specific neural networks are associated with different sets of susceptibility genes. If this is the case, endophenotypes may help identify biologically meaningful subtypes of schizophrenia linked to specific genotypes, thereby providing a clearer link between genetic and phenotypic variation²⁴.

Brief Introduction to the Human Genome and Classes of Specific Genetic Variants

Recent genetic studies of AOS and COS have focused on identifying specific genetic factors that increase risk for schizophrenia. The ability to rigorously pursue such questions has accelerated rapidly since 2003, when the human genome was first sequenced and established as a reference genome to enable subsequent scientific discovery²⁵. Our understanding of the range of classes of genetic variants observed in the human population; the frequency at which different classes of variants exist in the average person's genome; and the overall genetic architecture of complex traits such as schizophrenia has improved dramatically since this landmark achievement. We now know that there are ~3 billion nucleotide base pairs (bp) in the human genome, comprised of the four nucleotide bases, adenine (A), cytosine (C), guanine (G), and thymine (G). Approximately 1.5% of this DNA sequence encodes proteins²⁶, which form the building blocks of every cell and organ in the human body. A substantial portion of the remaining DNA sequence encodes non-protein coding RNA transcripts or regulatory sequences that are critical for temporally and spatially regulating the expression of the ~20,000 protein-coding genes in the human genome. However,

estimates of the exact proportion of non-protein coding DNA having a functional role vary widely (e.g., less than 10% to up to 80%^{27–29}), and a significant portion of non-coding DNA likely has no functional role at all²⁹.

The vast majority of DNA sequence is identical between two individual humans (>99.8%)³⁰. Nevertheless, given the total length of the human genome, the average individual differs from the reference human genome at ~4–5 million locations in the genome³⁰, yielding a huge pool of variants to examine for potential association with psychiatric traits such as schizophrenia. Broadly, each variation in sequence can be categorized based on the frequency that it is observed in the population, the size and type of variant (e.g., number of affected nucleotides), and the functional consequence of the variant. Thus, common variants (i.e., traditionally defined as variants found in >5% of the population) are observed more frequently than rare variants (i.e., <0.5–1% of the population). Relatedly, single nucleotide variants (SNVs), which are called single nucleotide polymorphisms (SNPs) when they are common in a population, affect only one bp and are generally smaller or affect shorter DNA sequence than short insertions or deletions (i.e., indels; 1–49 bp in length). Short indels, in turn, are smaller than structural variants, which include inversions, translocations, deletions, and duplications of larger sequences of DNA (i.e., > 50 bp) that affect chromosomal structure³¹. Owing to the effect of natural selection, in which deleterious mutations impact the ability of an individual to mate and/or have viable offspring or are lethal altogether, common variants are less likely to have damaging effects compared to rare or de novo variants. However, new mutations, known as de novo mutations (DNMs), occur in every offspring (i.e., are not observed in either parent) and are thereby continuously introduced into the population. Thus, all individuals carry rare variants and DNMs. Indeed, while the majority of variants observed in a single individual's genome are common and small (>99.9% of variants), the average human genome also contains over 2,000 structural variants, and 40,000–200,000 rare variants (i.e., 1–4% of variants per genome)^{30,7}. Regardless of variant class or the frequency that a variant is observed in a population, the ultimate importance of a given variant rests on whether it exerts a molecular or phenotypic consequence, such as by qualitatively altering the structure of a protein and/or altering its level of expression³¹. The vast majority of variants are currently thought to have benign or minimal phenotypic consequences; however, annotating the functional consequences of a variant remains a complex task, particularly for non-protein coding regions of the genome.

These advances in our understanding of the range and scale of genetic variation present in the human genome have ushered in a new era of psychiatric genetics, focused largely on using agnostic, genome-wide approaches to identify variants associated with disease, as well as understanding how disease-associated variants disrupt biological processes to eventuate in disease. Given the frequency with which variants of all classes are observed in the average individual genome, finding robust associations between individual variants and complex traits is a major challenge. However, as new tools and standards for genetic studies have been developed and refined, psychiatric genetics has begun to yield major insights into the genetic architecture and specific variants associated with complex psychiatric traits such as AOS and COS.

The New Era of Psychiatric Genomics

Psychiatric genetics in the 1990s and 2000s was dominated by small to moderately-sized studies of candidate gene and linkage studies that frequently failed to replicate^{32–34}. In contrast, over the last decade, large-scale collaborative studies, often genotyping thousands to tens of thousands of minimally phenotyped patients and controls, have begun to identify many specific variants that are robustly associated with disease. The advent and eventual success of these large-scale studies was facilitated by technological improvements that dramatically reduced the cost of genome-wide genotyping and sequencing, as well as the realization that critical confounds such as SNPs occurring at varying rates in populations with different ancestries (i.e., which can lead to spurious associations if patient and control groups are not carefully matched in genetic ancestry), needed to be carefully accounted for in genetic studies³⁵.

Thus far, the majority of genome-wide association studies (GWAS) of schizophrenia have investigated different classes of genetic variants through independent studies (i.e., studying common, rare, or de novo variants separately). In addition, given that COS is a rare condition, existing studies largely involved AOS patients. In the following, we will therefore first review results from well-powered, seminal studies of the more typical AOS, for each broad class of genetic variants. We will also discuss evidence for the multifactorial/polygenic threshold model of risk for schizophrenia across variant classes. Finally, we will review studies that are specific to COS, as well as studies that explore genetic associations in relation to age of psychosis onset. We note that across this review of studies, we focus on findings based on genome-wide approaches, given the now well-established problems with replicability in candidate gene studies.

Overview of Genetic Studies of AOS

It is now clear that the genetic architecture of AOS is complex and high polygenic, involving hundreds to thousands of genes, with risk variants spanning the range of possible allelic frequencies and variant classes. Thus, in a seminal genome-wide association study (GWAS) of common variants in 36,989 schizophrenia cases and 113,075 controls, 108 independent loci were found to be significantly associated with schizophrenia status³⁶. While each significantly associated loci was found to confer only a small increase in risk (i.e., median odds ratio (OR) per associated SNP = 1.08), when the effects of all nominally associated ($p < .05$) loci were considered together as a single polygenic risk score (PRS), schizophrenia PRS was able to explain 18.4% of the variance in case versus control status³⁶. Interestingly, while 40% of the 108 significantly associated loci were located within the sequence boundaries of a single protein coding gene, the remaining associated SNPs were located in non-protein coding regions of the genome, and only 10 loci were credibly associated with non-synonymous polymorphisms predicted to directly alter the amino-acid sequence of a protein. This suggests that many common variants associated with AOS are likely to contribute to disease risk by altering the level of expression of specific proteins, rather than more directly altering protein structure. Notable genes implicated by associated loci included DRD2, which encodes the dopamine D2 receptor that is the primary target of almost all anti-psychotic drugs; numerous genes involved in glutamatergic signaling and

plasticity, including GRIA1, GRIN2A, and SRR; and genes encoding voltage-gated calcium channels, such as CACNA1C and CACNB2, thus providing genetic evidence for existing etiologic hypotheses of schizophrenia involving dopaminergic and glutamatergic signaling. These schizophrenia-associated variants were also found to map to genes that are expressed specifically in pyramidal neurons (i.e., the primary glutamatergic/excitatory neurons of the cortex), medium spiny neurons of the striatum (i.e., primary dopaminergic neurons), and cortical interneurons (i.e., primary GABAergic/inhibitory neurons)³⁷. A more recent meta-analytic GWAS of common variants in schizophrenia included an additional 5,220 schizophrenia cases and 18,823 controls, and identified 145 independent loci significantly associated with schizophrenia³⁸. The identified schizophrenia-associated SNPs were enriched for genes that are intolerant to mutation (i.e., found to be very rarely mutated in humans, suggesting that mutation in these genes is under strong selective pressure), genes involved in synaptic transmission, and genes that are targets of the fragile X mental retardation protein (FMRP), which is known to regulate the protein-level expression of genes involved in brain development and synaptic plasticity. Together, these seminal studies provided compelling evidence that common risk variants for schizophrenia converge onto neuronal and synaptic gene-sets. As sample sizes continue to increase, the number of common variants significantly associated with AOS will continue to increase, along with our understanding of the convergent biological processes impacted by risk variants for AOS.

Studies of rare variants have also yielded insights into the genetic etiology of AOS, although given the inherent low frequency of individual rare variants, disease associations are generally tested after aggregating variants to summary levels such as the gene or gene-set level. Thus, schizophrenia patients have been found to carry an increased burden of rare³⁹ and ultra-rare⁴⁰ deleterious mutations, overall, compared to controls, although the effect size of this overall increased burden is relatively small (e.g., OR = 1.07 for damaging and disruptive ultra-rare variants⁴⁰). Nevertheless, aggregated at the gene-set level, rare deleterious mutations in schizophrenia patients were found to be enriched for genes that are intolerant to mutation, genes that are expressed specifically in neurons, gene targets of FMRP⁴¹, and genes that are components of synaptic gene-sets, such as the N-methyl-D-aspartate receptor (NMDAR) and activity-regulated cytoskeleton-associated protein (Arc) complexes^{39,40,42}, which are critically involved in modulating synaptic plasticity. Protein-altering DNMs in schizophrenia patients have been found to be similarly elevated in genes involved in neuronal and synaptic function, including genes that are components of the post-synaptic density, the NMDAR and Arc complexes, and targets of FMRP⁴³, as well as among genes involved in regulating the expression of other genes⁴⁴. Thus, compelling evidence indicates that damaging rare variants and DNMs in AOS also converge on genes involved in neuronal and synaptic function.

Copy number variants (CNVs) are a particular class of structural variants in which large segments of DNA are deleted or duplicated, resulting in genomic imbalances in the normal number of copies of DNA in the region. CNVs frequently arise in genomic “hotspot” regions that contain repeats of DNA sequence, known as segmental duplications, as these repeat DNA sequences make them prone to unequal crossing over during meiotic recombination (i.e., non-allelic homologous recombination). As an overall class, large (e.g., > 100 kb), rare CNVs (i.e., observed in <1% of the population) have been consistently associated with

schizophrenia (e.g., OR = 1.15;^{45,46}) and have yielded important insights into the genetic etiology schizophrenia^{45–50}. The overall increased burden of CNVs associated with schizophrenia is concentrated in CNVs that overlap genes⁴⁸ and several recurrent CNV loci have been associated with schizophrenia, including deletions at the 22q11.2, 2p16.3 (NRXN1), 3q29, 15q11.2, and 15q13.3 loci, duplications at the 16p11.2 and 7q11.23 loci, and deletions or duplications at the 1q21.1 and 7p36.3 (VIPR2) loci. About 2.5% of schizophrenia patients are estimated to carry CNVs at one or more schizophrenia-associated loci⁴⁹. Interestingly, CNVs at many of these specific loci have pleiotropic effects, as they are also associated with broader neurodevelopmental disorders such as autism spectrum disorder (ASD) and intellectual disability (ID)^{47,51,52}. Similar to common variants associated with schizophrenia, as well as other rare and de novo variants, schizophrenia-associated CNVs disproportionately affect neuronal and synaptic gene-sets⁵³, including components of the postsynaptic density, and NMDAR and Arc complexes,^{47,54} and sets of genes that are involved in excitatory and inhibitory neurotransmission⁵⁵.

Notably, while at the clinical population level, common variants are expected to account for the largest proportion of overall genetic liability for schizophrenia (30–50%), each individual common variant confers only a small increase in risk³⁶. Conversely, deleterious rare, de novo, and copy number variants may account for a smaller proportion of schizophrenia liability at the clinical population level; however, when present in a given individual, deleterious rare variants can increase risk substantially (e.g., ORs up to ~20–68 for the most highly penetrant CNVs⁴⁸). Growing evidence also indicates that common and rare variants interact to increase risk. Thus, the total burden of common schizophrenia-associated risk alleles that a given individual carries can be summarized by their schizophrenia PRS, which is calculated as their weighted sum of schizophrenia risk-associated SNP alleles based on recent GWAS (e.g.,³⁶). While schizophrenia patients have higher PRS than controls, regardless of CNV carrier status, patients who carry risk CNVs that have been previously associated with schizophrenia have lower PRS compared to patients without risk CNVs^{56,57}. Furthermore, the elevated burden of common schizophrenia risk alleles in patients who also carry risk CNVs was found to be inversely proportional to the effect size of the risk CNV⁵⁷. Similarly, schizophrenia patients with damaging de novo variants in genes that are intolerant to mutation or are associated with neurodevelopmental disorders more broadly, were found to have lower transmission of schizophrenia PRS from parents compared to patients without de novo variants in these genes⁵⁸.

Together, these findings suggest that there is significant heterogeneity in the specific risk variants carried by each individual AOS patient, and that risk variants converge across variants classes and the allelic frequency spectrum to increase risk in an additive manner. Overall, this is consistent with long-standing multifactorial/polygenic threshold models of schizophrenia which postulate that schizophrenia results when an accumulation of risk factors crosses a threshold of liability⁵⁹.

Genetic Studies of COS

Given that COS is rare, there are relatively few genetic studies of COS, and the majority of these focused on establishing the extent to which risk for COS is conferred through similar

genetic mechanisms as AOS. Interestingly, preliminary evidence suggests that in addition to sharing genetic risk factors with AOS, the genetic architecture of COS may include greater loading from variants that also confer risk for other neurodevelopmental disorders, such as ASD, ID, and epilepsy. Thus, in a study of 130 COS probands and 103 of their healthy siblings, COS probands were found to have significantly higher schizophrenia PRS than their siblings, as well as higher polygenic risk for ASD⁶⁰. Elevated rates of large CNVs have also been found in COS⁵⁰, including in CNVs associated with schizophrenia and other neurodevelopmental disorders. Of note, rates of large, rare CNVs appear to be higher in COS patients compared not only to controls, but also to patients with AOS. Thus, 11.9% of COS probands were estimated to have a neurodevelopmental disease-associated CNV compared to 1.5% of their healthy siblings and 1.4%–4.9% of adult-onset schizophrenia patients^{61–63}. In particular, a high number of COS probands have been found to carry CNVs at the well-known 22q11.2 locus, which is known to increase risk for multiple psychiatric and developmental disorders, including schizophrenia, ASD, ID and attention deficit hyperactivity disorder^{61–63}.

Studies of DNMs using exome sequencing in COS have been small; however, one study of 17 COS proband-parent trios found an overall protein-coding DNM rate of 1.17 per COS exome that was similar to rates found in other psychiatric diseases⁶⁴. Interestingly, DNMs in COS patients were found to be enriched in loss-of-function intolerant genes, similar to AOS and other neurodevelopmental disorders⁶⁴. Numerous DNMs were found in these small COS samples that affect genes implicated in broader neurodevelopmental disorders, including ATP1A3, which encodes a subunit of the neuron-specific ATP-dependent transmembrane sodium-potassium pump^{65,66}; UPF3B, which is involved in regulating nonsense-mediated decay of mRNAs⁶⁷; SRCAP, which is a component of the chromatin-remodeling SRCAP complex and can function as a transcriptional activator in Notch- and CREB-mediated transcription; and PNKP, which is involved in DNA-strand repair (Sanders: personal communication). Together, these initial studies suggest that DNMs in COS are enriched for neurodevelopmental-disorder associated genes; however, further research is needed to systematically test this specific hypothesis.

Interestingly, two moderately sized, independent studies (i.e., 2762 cases and 3187 controls⁶⁸ and 1067 patients and 1169 controls⁶⁹) that largely involved AOS patients found that earlier age of psychosis onset was *not* associated with higher schizophrenia PRS. Conversely, in one of these studies that also assessed environmental risk factors, a high loading of environmental risk from perinatal insult, head injury, and/or cannabis use *was* associated with earlier psychosis onset⁶⁹. Given that “earlier-onset” patients in these studies appeared to generally involve patients with adolescent or early-adult onset, this raises the intriguing possibility that the risk architecture of psychosis onset falling within an intermediate, adolescent range may include a greater accumulation of risk from environmental factors compared to later psychosis onset in early- to mid-adulthood. Conversely, as noted above, the genetic architecture of COS may be characterized by a joint loading of variants that confer risk for AOS, as well as variants that are strongly associated with early-onset neurodevelopmental disorders such as ASD and ID. This is consistent with the elevated rates of autism spectrum or pervasive developmental disorder diagnoses found among COS patients^{70–72}. Together, this raises the possibility that different genetic and

environmental risk architectures may underlie childhood-, versus adolescent-, versus adult-onset of schizophrenia. However, this is largely speculative. Large-scale studies that concurrently assess various environmental risk factors and a comprehensive range of genetic variants associated with AOS and early neurodevelopmental disorders in large samples of schizophrenia patients whose ages of onset span the full range possible are needed to elucidate the risk architecture and specific genetic variants underlying variation in age of psychosis onset.

Summary and Implications for Clinical Practice

Overall, the extant literature suggests that the risk architecture of COS involves contributions from common variants that are associated with AOS, common variants that are associated with ASD, and a potentially higher contribution from large, rare CNVs that are associated with multiple neurodevelopmental disorders including schizophrenia, ASD, and ID, relative to AOS.

As the cost of genotyping and sequencing continues to fall, and our knowledge of the genetic etiology of COS, specifically, as well as schizophrenia, more broadly, and other neurodevelopmental disorders continues to improve, the promise of using genetic information to refine our diagnostic categories and develop individualized treatments for COS is increasingly salient⁷³. Indeed, harnessing the power of next generation sequencing to accelerate biomedical discovery and develop better targeted treatments that leverage genetic and molecular information at the individual patient level is a driving force behind the 2015 NIH Precision Medicine Initiative⁷⁴. Precision medicine approaches have already been incorporated into drug discovery trials and patient care in other areas of medicine. This is most notable for cancer, where screening for known highly penetrant genetic mutations and molecular profiling of tumors is beginning to impact clinical decision-making and guide the development and use of targeted therapies for specific tumor subtypes^{75–77}.

The path to precision medicine in psychiatry has a considerable way to go before gene discovery successes are translated into individualized treatments. Nevertheless, one early target for genomic screening might be for COS patients with notable developmental characteristics, such as facial dysmorphology, intellectual disability, language delay, or health problems such as congenital heart defects that are linked to CNV-related syndromes (e.g., 22q11.2, 3q29, or 15q11.2 deletion syndrome). Even in the absence of current, direct treatment implications, genetic testing to assess for the presence of potential pathogenic CNVs may be useful for improving patient and caregiver knowledge of disease etiology, as well as improving accessing to medical benefits and social services^{78,79}. As major advances in gene discovery continue in the coming years, identifying convergent pathways through which multiple genes associated with COS adversely impact brain development and function offers great promise for developing novel therapeutic targets for this debilitating condition.

Disclosures and Funding sources:

Robert Asarnow: Della Martin Foundation, NIMH grant MH72697

Jennifer Forsyth: NIMH K08MH118577; NARSAD Young Investigator Award

References

1. Burd L, Kerbeshian J. A North Dakota prevalence study of schizophrenia presenting in childhood. *J Am Acad Child Adolesc Psychiatry*. 1987;26(3):347–350. doi: 10.1097/00004583-198705000-00012 [PubMed: 3496327]
2. McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. *Epidemiol Rev*. 2008;30:67–76. doi:10.1093/epirev/mxn001 [PubMed: 18480098]
3. Edition F, et al. Diagnostic and statistical manual of mental disorders. Am Psychiatric Assoc. 2013 <https://dsm.psychiatryonline.org/doi/pdf/10.1176/appi.books.9780890420249.dsm-iv-tr>.
4. Kendler KS, Diehl SR. The genetics of schizophrenia: a current, genetic-epidemiologic perspective. *Schizophr Bull*. 1993;19(2):261–285. doi:10.1093/schbul/19.2.261 [PubMed: 8322035]
5. Tsuang M. Schizophrenia: genes and environment. *Biol Psychiatry*. 2000;47(3):210–220. <https://www.ncbi.nlm.nih.gov/pubmed/10682218>. [PubMed: 10682218]
6. Kallmann FJ, Roth B. Genetic aspects of preadolescent schizophrenia. *Am J Psychiatry*. 1956;112(8):599–606. doi:10.1176/ajp.112.8.599 [PubMed: 13292546]
7. Asarnow RF, Nuechterlein KH, Fogelson D, et al. Schizophrenia and schizophrenia-spectrum personality disorders in the first-degree relatives of children with schizophrenia: the UCLA family study. *Arch Gen Psychiatry*. 2001;58(6):581–588. <https://www.ncbi.nlm.nih.gov/pubmed/11386988>. [PubMed: 11386988]
8. Nicolson R, Brookner FB, Lenane M, et al. Parental Schizophrenia Spectrum Disorders in Childhood-Onset and Adult-Onset Schizophrenia. *American Journal of Psychiatry*. 2003;160(3):490–495. doi:10.1176/appi.ajp.160.3.490 [PubMed: 12611830]
9. Kendler KS, McGuire M, Gruenberg AM, O'Hare A, Spellman M, Walsh D. The Roscommon Family Study. I. Methods, diagnosis of probands, and risk of schizophrenia in relatives. *Arch Gen Psychiatry*. 1993;50(7):527–540. <https://www.ncbi.nlm.nih.gov/pubmed/8317947>. [PubMed: 8317947]
10. Baron M, Gruen R, Asnis L, Lord S. Familial transmission of schizotypal and borderline personality disorders. *Am J Psychiatry*. 1985;142(8):927–934. doi:10.1176/ajp.142.8.927 [PubMed: 4025588]
11. Gottesman II, Shields J. Genetic theorizing and schizophrenia. *Br J Psychiatry*. 1973;122(566):15–30. <https://www.ncbi.nlm.nih.gov/pubmed/4683020>. [PubMed: 4683020]
12. Nenadic I, Gaser C, Sauer H. Heterogeneity of brain structural variation and the structural imaging endophenotypes in schizophrenia. *Neuropsychobiology*. 2012;66(1):44–49. doi: 10.1159/000338547 [PubMed: 22797276]
13. Cannon TD. The inheritance of intermediate phenotypes for schizophrenia. *Curr Opin Psychiatry*. 2005;18(2):135–140. <https://www.ncbi.nlm.nih.gov/pubmed/16639165>. [PubMed: 16639165]
14. Allen AJ, Griss ME, Folley BS, Hawkins KA, Pearlson GD. Endophenotypes in schizophrenia: a selective review. *Schizophr Res*. 2009;109(1–3):24–37. doi:10.1016/j.schres.2009.01.016 [PubMed: 19223268]
15. Asarnow RF, Nuechterlein KH, Subotnik KL, et al. Neurocognitive impairments in nonpsychotic parents of children with schizophrenia and attention-deficit/hyperactivity disorder: the University of California, Los Angeles Family Study. *Arch Gen Psychiatry*. 2002;59(11):1053–1060. <https://jamanetwork.com/journals/jamapsychiatry/article-abstract/206880>. [PubMed: 12418939]
16. Gochman PA, Greenstein D, Sporn A, et al. Childhood onset schizophrenia: familial neurocognitive measures. *Schizophr Res*. 2004;71(1):43–47. doi:10.1016/j.schres.2004.01.012 [PubMed: 15374571]
17. Sporn A, Greenstein D, Gogtay N, et al. Childhood-onset schizophrenia: smooth pursuit eye-tracking dysfunction in family members. *Schizophr Res*. 2005;73(2–3):243–252. doi:10.1016/j.schres.2004.07.020 [PubMed: 15653267]
18. Wagshal D, Knowlton BJ, Cohen JR, et al. Deficits in probabilistic classification learning and liability for schizophrenia. *Psychiatry Res*. 2012;200(2–3):167–172. doi:10.1016/j.psychres.2012.06.009 [PubMed: 22763090]

19. Waltzman D, Knowlton BJ, Cohen JR, Bookheimer SY, Bilder RM, Asarnow RF. DTI microstructural abnormalities in adolescent siblings of patients with childhood-onset schizophrenia. *Psychiatry Res Neuroimaging*. 2016;258:23–29. doi:10.1016/j.psychres.2016.10.010 [PubMed: 27829189]
20. Wagshal D, Knowlton BJ, Cohen JR, et al. Cognitive correlates of gray matter abnormalities in adolescent siblings of patients with childhood-onset schizophrenia. *Schizophr Res*. 2015;161(2–3): 345–350. doi:10.1016/j.schres.2014.12.006 [PubMed: 25541139]
21. Mattai AA, Weisinger B, Greenstein D, et al. Normalization of cortical gray matter deficits in nonpsychotic siblings of patients with childhood-onset schizophrenia. *J Am Acad Child Adolesc Psychiatry*. 2011;50(7):697–704. doi:10.1016/j.jaac.2011.03.016 [PubMed: 21703497]
22. Asarnow RF, Nuechterlein KH, Asamen J, et al. Neurocognitive functioning and schizophrenia spectrum disorders can be independent expressions of familial liability for schizophrenia in community control children: the UCLA family study. *Schizophr Res*. 2002;54(1–2):111–120. <https://www.ncbi.nlm.nih.gov/pubmed/11853985>. [PubMed: 11853985]
23. Bigdeli Tim B., Nuechterlein Keith H., Sugar Catherine A., Subotnik Kenneth L., Kubarych Thomas, Neale Michael C., Kendler Kenneth S., and Asarnow Robert F. Evidence of shared familial factors influencing neurocognitive endophenotypes in adult- and childhood-onset schizophrenia. *Psychol Med*.
24. Greenwood TA, Lazzeroni LC, Murray SS, et al. Analysis of 94 candidate genes and 12 endophenotypes for schizophrenia from the Consortium on the Genetics of Schizophrenia. *Am J Psychiatry*. 2011;168(9):930–946. <https://ajp.psychiatryonline.org/doi/abs/10.1176/appi.ajp.2011.10050723>. [PubMed: 21498463]
25. Collins FS, Morgan M, Patrinos A. The Human Genome Project: lessons from large-scale biology. *Science*. 2003;300(5617):286–290. doi:10.1126/science.1084564 [PubMed: 12690187]
26. Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. *Nature*. 2001;409(6822):860–921. doi:10.1038/35057062 [PubMed: 11237011]
27. ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. *Nature*. 2012;489(7414):57–74. doi:10.1038/nature11247 [PubMed: 22955616]
28. Rands CM, Meader S, Ponting CP, Lunter G. 8.2% of the Human genome is constrained: variation in rates of turnover across functional element classes in the human lineage. *PLoS Genet*. 2014;10(7):e1004525. doi:10.1371/journal.pgen.1004525 [PubMed: 25057982]
29. Kellis M, Wold B, Snyder MP, et al. Defining functional DNA elements in the human genome. *Proc Natl Acad Sci U S A*. 2014;111(17):6131–6138. doi:10.1073/pnas.1318948111 [PubMed: 24753594]
30. 1000 Genomes Project Consortium, Auton A, Brooks LD, et al. A global reference for human genetic variation. *Nature*. 2015;526(7571):68–74. doi:10.1038/nature15393 [PubMed: 26432245]
31. Lappalainen T, Scott AJ, Brandt M, Hall IM. Genomic Analysis in the Age of Human Genome Sequencing. *Cell*. 2019;177(1):70–84. doi:10.1016/j.cell.2019.02.032 [PubMed: 30901550]
32. Owen MJ, Cardno AG. Psychiatric genetics: progress, problems, and potential. *Lancet*. 1999;354 Suppl 1:SI11–SI14. doi:10.1016/s0140-6736(99)90242-8 [PubMed: 10437849]
33. NCI-NHGRI Working Group on Replication in Association Studies, Chanock SJ, Manolio T, et al. Replicating genotype-phenotype associations. *Nature*. 2007;447(7145):655–660. doi:10.1038/447655a [PubMed: 17554299]
34. Arango C Candidate gene associations studies in psychiatry: time to move forward. *Eur Arch Psychiatry Clin Neurosci*. 2017;267(1):1–2. doi:10.1007/s00406-016-0765-7
35. Hellwege JN, Keaton JM, Giri A, Gao X, Velez Edwards DR, Edwards TL. Population Stratification in Genetic Association Studies. *Curr Protoc Hum Genet*. 2017;95:1.22.1–1.22.23. doi:10.1002/cphg.48
36. Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. *Nature*. 2014;511(7510):421–427. doi:10.1038/nature13595 [PubMed: 25056061]
37. Skene NG, Bryois J, Bakken TE, et al. Genetic identification of brain cell types underlying schizophrenia. *Nat Genet*. 5 2018. doi:10.1038/s41588-018-0129-5

38. Pardiñas AF, Holmans P, Pocklington AJ, et al. Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection. *Nat Genet.* 2018; doi:10.1038/s41588-018-0059-2
39. Loohuis LMO, Vorstman JAS, Ori AP, et al. Genome-wide burden of deleterious coding variants increased in schizophrenia. *Nat Commun.* 2015;6:7501. doi:10.1038/ncomms8501 [PubMed: 26158538]
40. Genovese G, Fromer M, Stahl EA, et al. Increased burden of ultra-rare protein-altering variants among 4,877 individuals with schizophrenia. *Nat Neurosci.* 2016;19(11):1433–1441. doi: 10.1038/nn.4402 [PubMed: 27694994]
41. Richards AL, Leonenko G, Walters JT, et al. Exome arrays capture polygenic rare variant contributions to schizophrenia. *Hum Mol Genet.* 2016;25(5):1001–1007. doi:10.1093/hmg/ddv620 [PubMed: 26740555]
42. Purcell SM, Moran JL, Fromer M, et al. A polygenic burden of rare disruptive mutations in schizophrenia. *Nature.* 2014;506(7487):185–190. doi:10.1038/nature12975 [PubMed: 24463508]
43. Fromer M, Pocklington AJ, Kavanagh DH, et al. De novo mutations in schizophrenia implicate synaptic networks. *Nature.* 2014;506(7487):179–184. doi:10.1038/nature12929 [PubMed: 24463507]
44. McCarthy SE, Gillis J, Kramer M, et al. De novo mutations in schizophrenia implicate chromatin remodeling and support a genetic overlap with autism and intellectual disability. *Mol Psychiatry.* 2014;19(6):652–658. doi:10.1038/mp.2014.29 [PubMed: 24776741]
45. International Schizophrenia Consortium. Rare chromosomal deletions and duplications increase risk of schizophrenia. *Nature.* 2008;455(7210):237–241. doi:10.1038/nature07239 [PubMed: 18668038]
46. Kirov G, Grozeva D, Norton N, et al. Support for the involvement of large copy number variants in the pathogenesis of schizophrenia. *Hum Mol Genet.* 2009;18(8):1497–1503. doi:10.1093/hmg/ddp043 [PubMed: 19181681]
47. Kirov G, Rees E, Walters JTR, et al. The penetrance of copy number variations for schizophrenia and developmental delay. *Biol Psychiatry.* 2014;75(5):378–385. doi:10.1016/j.biopsych.2013.07.022 [PubMed: 23992924]
48. Marshall CR, Howrigan DP, Merico D, et al. Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects. *Nat Genet.* 2017;49(1):27–35. doi: 10.1038/ng.3725 [PubMed: 27869829]
49. Rees E, Walters JTR, Georgieva L, et al. Analysis of copy number variations at 15 schizophrenia-associated loci. *Br J Psychiatry.* 2014;204(2):108–114. doi:10.1192/bjp.bp.113.131052 [PubMed: 24311552]
50. Walsh T, McClellan JM, McCarthy SE, et al. Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. *Science.* 2008;320(5875):539–543. doi:10.1126/science.1155174 [PubMed: 18369103]
51. Sanders SJ, He X, Willsey AJ, et al. Insights into Autism Spectrum Disorder Genomic Architecture and Biology from 71 Risk Loci. *Neuron.* 2015;87(6):1215–1233. doi:10.1016/j.neuron.2015.09.016 [PubMed: 26402605]
52. Rees E, Kendall K, Pardiñas AF, et al. Analysis of Intellectual Disability Copy Number Variants for Association With Schizophrenia. *JAMA Psychiatry.* 2016;73(9):963–969. doi:10.1001/jamapsychiatry.2016.1831 [PubMed: 27602560]
53. Forsyth JK, Nachun D, Gandal MJ, et al. Synaptic and Gene Regulatory Mechanisms in Schizophrenia, Autism, and 22q11.2 CNV Mediated Risk for Neuropsychiatric Disorders. *bioRxiv.* 2019:555490. doi:10.1101/555490
54. Kirov G, Pocklington AJ, Holmans P, et al. De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia. *Mol Psychiatry.* 2012;17(2):142–153. doi:10.1038/mp.2011.154 [PubMed: 22083728]
55. Pocklington AJ, Rees E, Walters JTR, et al. Novel Findings from CNVs Implicate Inhibitory and Excitatory Signaling Complexes in Schizophrenia. *Neuron.* 2015;86(5):1203–1214. doi:10.1016/j.neuron.2015.04.022 [PubMed: 26050040]

56. Tansey KE, Rees E, Linden DE, et al. Common alleles contribute to schizophrenia in CNV carriers. *Mol Psychiatry*. 2016;21(8):1085–1089. doi:10.1038/mp.2015.143 [PubMed: 26390827]
57. Bergen SE, Ploner A, Howrigan D, et al. Joint Contributions of Rare Copy Number Variants and Common SNPs to Risk for Schizophrenia. *Am J Psychiatry*. 11 2018:appiajp201817040467. doi: 10.1176/appi.ajp.2018.17040467
58. Rees E, Han J, Morgan J, et al. Analyses of rare and common alleles in parent-proband trios implicate rare missense variants in SLC6A1 in schizophrenia and confirm the involvement of loss of function intolerant and neurodevelopmental disorder genes. *bioRxiv*. 4 2019:607549. doi: 10.1101/607549
59. McGue M, Gottesman II, Rao DC. The transmission of schizophrenia under a multifactorial threshold model. *Am J Hum Genet*. 1983;35(6):1161–1178. <https://www.ncbi.nlm.nih.gov/pubmed/6650500>. [PubMed: 6650500]
60. Ahn K, An SS, Shugart YY, Rapoport JL. Common polygenic variation and risk for childhood-onset schizophrenia. *Mol Psychiatry*. 2014;21:94. doi:10.1038/mp.2014.158 [PubMed: 25510512]
61. Ahn K, Gotay N, Andersen TM, et al. High rate of disease-related copy number variations in childhood onset schizophrenia. *Mol Psychiatry*. 2014;19(5):568–572. doi:10.1038/mp.2013.59 [PubMed: 23689535]
62. Sagar A, Bishop JR, Tessman DC, Guter S, Martin CL, Cook EH. Co-occurrence of autism, childhood psychosis, and intellectual disability associated with a de novo 3q29 microdeletion. *Am J Med Genet A*. 2013;161(4):845–849. <https://onlinelibrary.wiley.com/doi/abs/10.1002/ajmg.a.35754>.
63. Vorstman JAS, Morcus MEJ, Duijff SN, et al. The 22q11.2 deletion in children: high rate of autistic disorders and early onset of psychotic symptoms. *J Am Acad Child Adolesc Psychiatry*. 2006;45(9):1104–1113. doi:10.1097/01.chi.0000228131.56956.c1 [PubMed: 16926618]
64. Ambalavanan A, Girard SL, Ahn K, et al. De novo variants in sporadic cases of childhood onset schizophrenia. *Eur J Hum Genet*. 2016;24(6):944–948. doi:10.1038/ejhg.2015.218 [PubMed: 26508570]
65. Chaumette B, Ferrafiat V, Ambalavanan A, et al. Missense variants in ATP1A3 and FXYD gene family are associated with childhood-onset schizophrenia. *Mol Psychiatry*. 6 2018. doi:10.1038/s41380-018-0103-8
66. Smedemark-Margulies N, Brownstein CA, Vargas S, et al. A novel de novo mutation in ATP1A3 and childhood-onset schizophrenia. *Cold Spring Harb Mol Case Stud*. 2016;2(5):a001008. doi: 10.1101/mcs.a001008 [PubMed: 27626066]
67. Jolly LA, Homan CC, Jacob R, Barry S, Gecz J. The UPF3B gene, implicated in intellectual disability, autism, ADHD and childhood onset schizophrenia regulates neural progenitor cell behaviour and neuronal outgrowth. *Hum Mol Genet*. 2013;22(23):4673–4687. doi:10.1093/hmg/ddt315 [PubMed: 23821644]
68. Bergen SE, O'Dushlaine CT, Lee PH, et al. Genetic modifiers and subtypes in schizophrenia: investigations of age at onset, severity, sex and family history. *Schizophr Res*. 2014;154(1–3):48–53. doi:10.1016/j.schres.2014.01.030 [PubMed: 24581549]
69. Stepniak B, Papiol S, Hammer C, et al. Accumulated environmental risk determining age at schizophrenia onset: a deep phenotyping-based study. *Lancet Psychiatry*. 2014;1(6):444–453. doi: 10.1016/S2215-0366(14)70379-7 [PubMed: 26361199]
70. Rapoport J, Chavez A, Greenstein D, Addington A, Gogtay N. Autism spectrum disorders and childhood-onset schizophrenia: clinical and biological contributions to a relation revisited. *J Am Acad Child Adolesc Psychiatry*. 2009;48(1):10–18. doi:10.1097/CHI.0b013e31818b1c63 [PubMed: 19218893]
71. Hollis C. Child and adolescent (juvenile onset) schizophrenia. A case control study of premorbid developmental impairments. *Br J Psychiatry*. 1995;166(4):489–495. doi:10.1192/bjp.166.4.489 [PubMed: 7795921]
72. Sporn AL, Addington AM, Gogtay N, et al. Pervasive developmental disorder and childhood-onset schizophrenia: comorbid disorder or a phenotypic variant of a very early onset illness? *Biol Psychiatry*. 2004;55(10):989–994. doi:10.1016/j.biopsych.2004.01.019 [PubMed: 15121482]

73. Gandal MJ, Leppa V, Won H, Parikshak NN, Geschwind DH. The road to precision psychiatry: translating genetics into disease mechanisms. *Nat Neurosci.* 2016;19(11):1397–1407. doi: 10.1038/nn.4409 [PubMed: 27786179]
74. Khoury MJ, Iademarco MF, Riley WT. Precision Public Health for the Era of Precision Medicine. *Am J Prev Med.* 2016;50(3):398–401. doi:10.1016/j.amepre.2015.08.031 [PubMed: 26547538]
75. Bettaieb A, Paul C, Plenchette S, Shan J, Chouchane L, Ghiringhelli F. Precision medicine in breast cancer: reality or utopia? *J Transl Med.* 2017;15(1):139. doi:10.1186/s12967-017-1239-z [PubMed: 28623955]
76. Dienstmann R, Vermeulen L, Guinney J, Kopetz S, Tejpar S, Tabernero J. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. *Nat Rev Cancer.* 2017;17(2):79–92. doi:10.1038/nrc.2016.126 [PubMed: 28050011]
77. Cardon LR, Harris T. Precision medicine, genomics and drug discovery. *Hum Mol Genet.* 2016;25(R2):R166–R172. doi:10.1093/hmg/ddw246 [PubMed: 27538422]
78. Bouwkamp CG, Kievit AJA, Markx S, et al. Copy Number Variation in Syndromic Forms of Psychiatric Illness: The Emerging Value of Clinical Genetic Testing in Psychiatry. *Am J Psychiatry.* 2017;174(11):1036–1050. doi:10.1176/appi.ajp.2017.16080946 [PubMed: 29088930]
79. Costain G, Chow EWC, Ray PN, Bassett AS. Caregiver and adult patient perspectives on the importance of a diagnosis of 22q11.2 deletion syndrome. *J Intellect Disabil Res.* 2012;56(6):641–651. doi:10.1111/j.1365-2788.2011.01510.x [PubMed: 22142442]

Key Points

1. Childhood-onset schizophrenia (COS) shares considerable genetic overlap with adult-onset schizophrenia (AOS).
2. The risk architecture of COS involves common and rare variants, including copy number variants (CNVs).
3. COS shares genetic overlap with earlier-onset neurodevelopmental disorders, such as autism spectrum disorder (ASD).
4. The utility of genetic screening for diagnosis and individualized treatment is currently limited; however, genetic testing may be useful in some cases and identifying common neural pathways upon which risk variants act offers promise towards developing novel interventions.

Synopsis

The genetic architecture of schizophrenia is complex and highly polygenic. This review discusses key findings from genetic studies of childhood-onset schizophrenia (COS) and the much more common adult-onset schizophrenia (AOS), including reviewing familial aggregation studies and studies of common, rare, and copy number variants. Extant literature suggests that COS is rare variant of AOS involving greater familial aggregation of schizophrenia spectrum disorders and a potentially higher occurrence of pathogenic copy number variants. The direct utility of genetics to clinical practice for COS is currently limited; however, identifying common pathways through which risk genes affect brain function offers promise for novel interventions.